Revenue
No reported data
Replimune Group, Inc. (REPL)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2019
2020
2021
2022
2023
2024
2025
2026
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | $221.2M | $189.4M | $175.0M | $126.5M | $79.5M | $56.8M | $38.8M | $22.2M | $13.5M | $6.9M |
| Operating expenses | $319.9M | $261.6M | $234.8M | $177.1M | $118.3M | $80.0M | $56.2M | $30.9M | $19.2M | $9.6M |
| Operating income | −$319.9M | −$261.6M | −$234.8M | −$177.1M | −$118.3M | −$80.0M | −$56.2M | −$30.9M | −$19.2M | −$9.6M |
| EBITDAderived | −$316.6M | −$258.1M | −$232.1M | −$174.6M | −$116.2M | −$78.2M | −$55.7M | −$30.8M | −$19.1M | −$9.5M |
| Net income | −$313.9M | −$247.3M | −$215.8M | −$174.3M | −$118.0M | −$80.9M | −$52.6M | −$30.8M | −$19.7M | −$7.7M |
| Basic EPSper diluted share | -$3.38 | -$3.07 | -$3.24 | -$2.99 | -$2.26 | -$1.75 | -$1.54 | -$1.33 | -$3.96 | -$1.55 |
| Diluted EPSper diluted share | -$3.38 | -$3.07 | -$3.24 | -$2.99 | -$2.26 | -$1.75 | -$1.54 | -$1.33 | -$3.96 | -$1.55 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 1, 2026Form 4 · 10b5-1 | Sarchi ChristopherChief Commercial Officer | SellCommon Stock | 12.0K | $9.24 | $110.9K | 181.0K |
| May 18, 2026Form 4 | Xynos KonstantinosChief Medical Officer | SellCommon Stock | 14.0K | $5.08 | $71.2K | 235.7K |
| May 18, 2026Form 4 | Schwendenman AndrewChief Accounting Officer | SellCommon Stock | 7.9K | $5.08 | $40.1K | 107.1K |
| May 18, 2026Form 4 | Sarchi ChristopherChief Commercial Officer | SellCommon Stock | 8.6K | $5.08 | $43.8K | 193.0K |
| May 18, 2026Form 4 | Astley-Sparke PhilipDirector | SellCommon Stock | 17.7K | $5.08 | $89.7K | 1.41M |